Why the study?
Does mavacamten improve tolerability and reduce biomarkers of myocardial wall stress in adults with symptomatic non-obstructive hypertrophic cardiomyopathy?
Does mavacamten improve tolerability and reduce biomarkers of myocardial wall stress in adults with symptomatic non-obstructive hypertrophic cardiomyopathy?
In a Phase 2 study, mavacamten was well tolerated and significantly reduced biomarkers of myocardial wall stress (NT-proBNP and cTnI) in patients with symptomatic non-obstructive HCM.
No takes yet. Share an insight, caveat, or question.
Supports Phase 3 trials in non-obstructive HCM; extends tolerability and biomarker data beyond obstructive cohorts.
Ho et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: